Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2

Table 3 Estimates obtained from Core Model (\(\gamma =1/7\))

Parameter	Median (50%)	Lower (2.5%)	Upper (97.5%)
\(\beta\)	0.4060	0.3893	0.4425
\(e_{1A}\)	0.3851	0.3425	0.4260
\(e_{2A}\)	0.6402	0.6140	0.6647
\(e_{1P}\)	0.1954	0.1041	0.2809
\(e_{2P}\)	0.8392	0.8212	0.8559
Initial I	54.0151	48.4328	59.5435
Initial \(I_{1A}\)	14.8932	10.3012	19.8382
Initial \(I_{2A}\)	2.4775	0.9300	4.7359
Initial \(I_{1P}\)	0.7469	0.1234	2.0681
Initial \(I_{2P}\)	2.9717	1.3856	5.1267

Notation is as follows \(\beta\): Transmission rate, \(e_{ij}\): Effectiveness of i doses of vaccine j against infection, Initial I: Initial number of unvaccinated infected individuals, Initial \(I_{ij}\): Initial number of infected individuals who have received i doses of vaccine j. For number of doses we have \(i\in \{1,2\}\) and for vaccines \(j\in \{A,P\}\) for Oxford-AstraZeneca and Pfizer-BioNTech respectively

ISSN: 1471-2334